| Drug Name |
Palonosetron |
| Drug ID |
BADD_D01659 |
| Description |
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. |
| Indications and Usage |
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation. |
| Marketing Status |
approved; investigational |
| ATC Code |
A04AA05 |
| DrugBank ID |
DB00377
|
| KEGG ID |
D07175
|
| MeSH ID |
D000077924
|
| PubChem ID |
6337614
|
| TTD Drug ID |
D04FVU
|
| NDC Product Code |
68001-355; 16714-834; 63323-673; 55111-694 |
| UNII |
5D06587D6R
|
| Synonyms |
Palonosetron | 2-QHBIQO | Palonosetron, (R-(R*,R*))-isomer | Palonosetron, (3R)- | Palonosetron, (R-(R*,S*))-isomer | RS 25259-198 | RS 25259 198 | RS 25259198 | RS-25259-198 | RS25259198 | 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one | RS 25233-198 | RS 25233 198 | RS 25233198 | RS-25233-198 | RS25233198 | RS 25259 | RS-25259 | RS25259 | RS 25259-197 | RS 25259 197 | RS 25259197 | RS-25259-197 | RS25259197 | Aloxi | Palonosetron, (S-(R*,S*))-isomer | Palonosetron Hydrochloride | RS 25233-197 | RS 25233 197 | RS 25233197 | RS-25233-197 | RS25233197 |
